Main findings
inflammation, infarct, myocardial injury
INFLAMMATION, INFARCT
The main findings were that (1) tocilizumab increased the concentrations of most cytokines in the acute phase compared with placebo; (2) a pronounced effect was observed for IL-6, IL-8 and IL-1ra also after adjusting for multiple comparisons and (3) the association between inflammation (IL-6 and IL-8) and myocardial injury (infarct size, TnT and MSI) was not observed in patients treated with tocilizumab. This association was primarily seen in placebo-treated patients who presented ≤3 hours from symptom onset.